The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA
Open accessAbstract
From the metal ions and metal compounds that are known to bind to DNA, many anticancer Pt(II) and Ru(II)/Ru(III) compounds are known to have ligand-exchange kinetics in the same order of magnitude as the division of tumor cells. The present article discusses this process in detail with special attention to cisplatin and related compounds and the cellular binding sites and processes of such compounds. Detailed platinated DNA structures are presented and discussed in light of the mechanistic studies of metal antitumor compounds. It is now known that platinum antitumor drugs eventually end up on the DNA. However, it remains a challenge to understand how (fast) they reach the DNA and how they are removed. The kinetics of ligand exchange around platinum appear to play a crucial role, and the possible role of other ligands as intermediates, especially those with S-donor sites, is of great interest. New types of Pt compounds with additional functionalities influencing DNA binding and kinetics are discussed in the context of steric and H-bonding properties. A comparison is made with more sterically crowded Ru complexes. The effects on activity and correlations with structural and kinetic properties are clues in understanding the biological activities of these classes of compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
Jamieson, E. R., & Lippard, S. J. (1999) · Chemical Reviews · doi:10.1021/cr980421n · Cited by 2,949
Current Status of Platinum-Based Antitumor Drugs
Wong, E., & Giandomenico, C. M. (1999) · Chemical Reviews · doi:10.1021/cr980420v · Cited by 1,800
Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug
(1999) · Wiley eBooks · doi:10.1002/9783906390420 · Cited by 1,296
Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., & Reedijk, J. (1985) · Biochemistry · doi:10.1021/bi00324a025 · Cited by 1,024
Self-citationUptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
Non-Platinum Chemotherapeutic Metallopharmaceuticals
Clarke, M. J., Zhu, F., & Frasca, D. R. (1999) · Chemical Reviews · doi:10.1021/cr9804238 · Cited by 908
Barry, M. A., Behnke, C. A., & Eastman, A. (1990) · Biochemical Pharmacology · doi:10.1016/0006-2952(90)90733-2 · Cited by 867
Inhibition of Cancer Cell Growth by Ruthenium(II) Arene Complexes
Morris, R. E., Aird, R. E., del Socorro Murdoch, P., Chen, H., Cummings, J., Hughes, N. D., Parsons, S., Parkin, A., Boyd, G., Jodrell, D. I., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010051m · Cited by 787
Cited by
Direct Cellular Responses to Platinum-Induced DNA Damage
Jung, Y., & Lippard, S. J. (2007) · Chemical Reviews · doi:10.1021/cr068207j · Cited by 1,391
Timerbaev, A. R., Hartinger, C. G., Aleksenko, S. S., & Keppler, B. K. (2006) · Chemical Reviews · doi:10.1021/cr040704h · Cited by 614
Using coordination chemistry to design new medicines
Ronconi, L., & Sadler, P. J. (2007) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2006.11.017 · Cited by 608
Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Frezza, M., Hindo, S., Chen, D., Davenport, A., Schmitt, S., Tomco, D., & Ping Dou, Q. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791209009 · Cited by 552
Ruthenium-based chemotherapeutics: are they ready for prime time?
Antonarakis, E. S., & Emadi, A. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1293-1 · Cited by 489
Interactions of Metal−Metal-Bonded Antitumor Active Complexes with DNA Fragments and DNA
Chifotides, H. T., & Dunbar, K. R. (2005) · Accounts of Chemical Research · doi:10.1021/ar0302078 · Cited by 445
Lazarević, T., Rilak, A., & Bugarčić, Ž. D. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.04.007 · Cited by 428
Alessio, E. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600986 · Cited by 388
Anti-cancer palladium complexes: a focus on PdX2L2, palladacycles and related complexes
Kapdi, A. R., & Fairlamb, I. J. S. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00063c · Cited by 379
Leijen, S., Burgers, S. A., Baas, P., Pluim, D., Tibben, M., van Werkhoven, E., Alessio, E., Sava, G., Beijnen, J. H., & Schellens, J. H. M. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0179-1 · Cited by 374
Organometallic Half-Sandwich Iridium Anticancer Complexes
Liu, Z., Habtemariam, A., Pizarro, A. M., Fletcher, S. A., Kisova, A., Vrana, O., Salassa, L., Bruijnincx, P. C. A., Clarkson, G. J., Brabec, V., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2000932 · Cited by 357
Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs
Liu, W., & Gust, R. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.09.004 · Cited by 351
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
Reedijk, J. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200900054 · Cited by 343
Self-citationGeorge, S., Xia, T., Rallo, R., Zhao, Y., Ji, Z., Lin, S., Wang, X., Zhang, H., France, B., Schoenfeld, D., et al. (2011) · ACS Nano · doi:10.1021/nn102734s · Cited by 326
Metal-based drugs that break the rules
Allardyce, C. S., & Dyson, P. J. (2016) · Dalton Transactions · doi:10.1039/c5dt03919c · Cited by 308
Wang, F., Habtemariam, A., van der Geer, E. P. L., Fernández, R., Melchart, M., Deeth, R. J., Aird, R., Guichard, S., Fabbiani, F. P. A., Lozano-Casal, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505798102 · Cited by 308
Metal complexes in medicinal chemistry: new vistas and challenges in drug design
Thompson, K. H., & Orvig, C. (2006) · Dalton Trans. · doi:10.1039/b513476e · Cited by 298
Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity
Zutphen, S. V., & Reedijk, J. (2005) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2005.03.005 · Cited by 295
Self-citationBaik, M.-H., Friesner, R. A., & Lippard, S. J. (2003) · Journal of the American Chemical Society · doi:10.1021/ja036960d · Cited by 293
Arnesano, F., & Natile, G. (2009) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2009.01.028 · Cited by 282
Mechanistic Studies of Metal Aqua Ions: A Semi‐Historical Perspective
Lincoln, S. F. (2005) · Helvetica Chimica Acta · doi:10.1002/hlca.200590036 · Cited by 110
Metadata
- Authors
- Reedijk, J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-03-24
- Volume
- 100
- Issue
- 7
- Pages
- 3611-3616
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2093282189
- Cited by
- 617
- References
- 43
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.